UNSPSC 51152038: Mivacurium chyloride

This classification denotes a muscle relaxant with the molecular formula C58H80N2O14.2Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 600ZG213C3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but generally known as mivacurium chloride, which bears US NIH Compound Identifier 5281080.

UNSPSC 51152038 Mivacurium chloride is a Commodity code that covers a single pharmaceutical product used in anesthesia and critical care settings. Recent state and local activity under this code shows minimal alignment with the nominal product scope — the two most recent opportunities posted by state and local bodies involve naloxone procurement and therapeutic pharmacy initiative infrastructure rather than mivacurium chloride specifically. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission posted an RFI for direct-to-manufacturer prescription fulfillment capabilities. Neither solicitation targets the anesthetic agent named in the code. State and local procurement under this code appears driven primarily by health departments, county health authorities, and state HHS agencies seeking emergency-response pharmaceuticals and pharmacy benefit innovations rather than operating-room or critical-care anesthetics.

Activity under this code is geographically sparse and recent-opportunity data is limited. The two posted opportunities span Florida and Texas, with no other states represented in the available record. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with electronic bid submission required and a two-year initial term plus one-year renewal option. The Texas HHS Commission RFI (HHS0017013, issued April 3, 2026) was exploratory in nature, gathering vendor capabilities for a future direct-to-manufacturer pharmacy program rather than committing to a specific product purchase. The mismatch between the code's pharmaceutical scope and the actual procurement focus suggests this code may not be the appropriate taxonomy tier for state and local emergency-response or pharmacy-benefit solicitations, or that the opportunities were miscoded at posting.